• Publications
  • Influence
Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
Objectives Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was toExpand
  • 151
  • 8
Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
Objective To determine the diagnostic and prognostic performance of serum neurofilament light chain (NFL) in amyotrophic lateral sclerosis (ALS). Methods This single-centre, prospective, longitudinalExpand
  • 61
  • 5
Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases
Abstract TAR DNA-binding protein 43 (TDP-43) is one of the neuropathological hallmarks in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). It is present in patients’Expand
  • 88
  • 3
Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
Objective To examine neurofilament (Nf) concentrations according to symptom onset and clinical diagnostic certainty categories of amyotrophic lateral sclerosis (ALS). Methods We measured Nf lightExpand
  • 73
  • 3
  • PDF
Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.
The impairment of the ubiquitin-proteasome system (UPS) is thought to be an early event in neurodegeneration, and monitoring UPS alterations might serve as a disease biomarker. Our aim was toExpand
  • 29
  • 3
Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression
Objectives Neurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, staging and prediction of outcome. We aimed at determiningExpand
  • 38
  • 2
Towards a TDP-43-Based Biomarker for ALS and FTLD
TDP-43 accumulates in nerve cells of nearly all cases of amyotrophic lateral sclerosis (ALS; the commonest form of motor neuron disease) and in the majority of Tau-negative frontotemporal lobarExpand
  • 36
  • 1
Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD
The loss-of-function mechanism in progranulin (PGRN) mutation carriers makes PGRN an interesting target for upregulation as a therapeutic approach in neurodegenerative diseases like frontotemporalExpand
  • 21
  • 1
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update
Frontotemporal lobar degeneration (FTLD) is a spectrum of rare neurodegenerative diseases with overlapping symptoms and neuropathology. It includes the behavioral variant of frontotemporal dementiaExpand
  • 20
  • 1
Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives.
Frontotemporal lobar degeneration (FTLD) comprises a spectrum of rare neurodegenerative diseases with an estimated prevalence of 15-22 cases per 100,000 persons including the behavioral variant ofExpand
  • 15
  • 1